Company ProfilePremium

Radiopharm Theranostics Limited

Company Profile Analysis

Ticker: RAD.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Radiopharm Theranostics Limited - Company showcase

Year Founded & Workforce

2021

14 Employees

Radiopharm Theranostics Limited logo

Radiopharm Theranostics Limited Employee Contacts

7 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Radiopharm Theranostics Limited Overview

Radiopharm Theranostics is a capital-light, clinical-stage radiopharmaceutical developer that has assembled, primarily by in-licensing from academic centres, a portfolio spanning one late-stage diagnostic and five clinical-stage or near-clinical therapeutic and imaging programs. Its strategic thesis is to compete outside the crowded PSMA and somatostatin-receptor franchises by pairing less-exploited tumour targets (fatty acid synthase, HER2, PD-L1, αvβ6-integrin, the 4Ig isoform of B7-H3, and KLK3) with a range of isotopes (fluorine-18, gallium-68, lutetium-177, terbium-161) and molecular formats (small molecules, peptides, nanobodies and monoclonal antibodies). The lead asset, RAD101, an F-18 PET tracer for distinguishing recurrent brain metastases from post-radiotherapy treatment effects, holds FDA Fast Track designation, met its Phase 2b primary endpoint in July 2026, and completed an End-of-Phase 2 meeting with the FDA in October 2026. The company's investment case is therefore a near-term Phase 3 diagnostic catalyst set against an acute funding constraint and heavy shareholder dilution.


What the company does. Radiopharm researches and develops radiopharmaceuticals — molecules that carry a radioactive isotope to a tumour-associated target — for two purposes: diagnostic imaging (PET tracers labelled with F-18 or Ga-68) and targeted radionuclide therapy (beta- or Auger-emitting isotopes such as Lu-177 and Tb-161). The FY2026 20-F describes the company as a clinical-stage radiotherapeutics company focused on diagnostic and therapeutic products for areas of high unmet medical need, with no product approved for sale and no product revenue expected until approval and launch.

Company's own characterisation (paraphrased from the FY2025/FY2026 20-F business summaries and press-release boilerplate). The company presents itself as building a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications. The FY2025 20-F summary describes six licensed platform technologies plus a joint venture with The University of Texas MD Anderson Cancer Center, with programs in Phase 1 and Phase 2 across breast, lung, pancreatic, prostate cancer, brain metastases and glioblastoma, and development activity in the United States, Australia, the European Union and other markets. Recent investor materials (July 2026) describe the company as a multi-asset platform with a Phase 3-ready imaging lead and four clinical-stage therapeutics.

Business model. Pure research-and-development model with no manufacturing, commercial or sales infrastructure. The company in-licenses intellectual property (Imperial College London / Cancer Research Technology, NanoMab Technology, Diaprost/Fredax, TRIMT, NeoIndicate, MD Anderson), funds clinical development through contract research organisations (GenesisCare, Medpace per Zacks SCR) and contract manufacturers/isotope suppliers (Siemens Healthineers, ITM, Cyclotek, TerThera and others), and aims to monetise through either self-commercialisation (most plausibly for RAD101 in the US) or partnering/out-licensing.

Revenue model and mix.

Value-chain position. Upstream innovator: target selection, molecule optimisation, clinical development and regulatory strategy. It sits between academic licensors (upstream) and isotope producers, radiopharmacies and CMOs (supply chain), with eventual customers being nuclear-medicine departments, PET imaging centres and oncologists.

Customer types and end-markets (prospective). Hospitals and imaging centres (neuro-oncology and radiation-oncology services for RAD101), oncology treatment centres (therapeutics), and payers (CMS and private insurers in the US; PBS-type regimes ex-US). Current revenue customer: one counterparty (Lantheus), i.e. 100% customer concentration.

Independent characterisation. Radiopharm is best understood as a micro-cap option portfolio on target-isotope combinations whose value is overwhelmingly concentrated in a single near-registrational diagnostic (RAD101). The therapeutic pipeline is broad but early (Phase 1 dose escalation), and the company's balance sheet — A$4.1M cash at 30 June 2026 against A$52.8M operating cash burn — means the strategic agenda is dictated by financing. Its in-licensing model has produced breadth cheaply, but carries contingent milestone obligations (A$25.8M of contingent consideration liabilities at 30 June 2026) and royalty leakage on any eventual product.

Strategy

Stated strategic themes (paraphrased from 20-F, investor presentations and releases)

  1. Go beyond validated targets. Develop radiopharmaceuticals for tumours and targets outside the prostate, thyroid and neuroendocrine indications already validated by approved products, using precision-oncology rationale.

  2. Pair novel targets with underused isotopes. Use F-18, Ga-68, Lu-177 and Tb-161 to improve on-target activity and efficacy.

  3. Be first in clinic in each target class. Management emphasised in March 2026 that each therapeutic is intended to be first in clinical development in its niche.

  4. Asset-light, partner-heavy execution. Outsource manufacturing, isotope supply and clinical operations; leverage strategic partners (Lantheus, Siemens Healthineers, MD Anderson).

  5. Advance RAD101 to registration. Be Phase 3-ready by year-end 2026 and run a multi-centre, multi-country registrational trial.

  6. Strategic partnering. "Ongoing strategic partnering initiatives" are a stated use of proceeds from the July 2026 raise.

Initiatives announced in the last 24 months

InitiativeDateDescriptionSource
Nasdaq listing of ADSsNov 2024Expand US investor access; no capital raisedStockTitan
Lantheus co-development partnership and development-services contractDec 2024 – FY2025Co-development with initial focus on a Phase 1 imaging trial; services contract in AustraliaStockhead; FY2026 Appendix 4E
Isotope supply securityFY2025Multiple supply agreements (ITM, SHINE, ANSTO, Isotopia, Cyclotek, TerThera)Zacks SCR; FY2025 results
Increase control of MD Anderson JVAug 2024; Jan 2026Stake to 75% then 87.5%FY2026 Appendix 4E
RV-01 and RAD402 first-in-human trialsFY2026Two additional Phase 1 therapeutic programs initiatedQ3 FY26 4C (Apr 2026)
Leerink ATMDec 2025Flexible US equity accessFY2026 20-F
Siemens Healthineers RAD101 supplyApr 2026Phase 3 manufacturing/distribution readinessPress release
Phase 3 readiness programOct 2026Executing readiness activities pending FDA minutes6-K 5 Oct 2026

Cost programs: No formal cost-reduction program announced. The 20-F notes management can delay or reduce operating activities as a cash-management lever.

ESG commitments: None published.

Management guidance and medium-term targets

ItemGuidanceSource
RAD101 FDA EOP2 minutesWithin ~30 days of 1 Oct 20266-K 5 Oct 2026
RAD101 Phase 3Phase 3-ready by YE2026; trial start targeted 4Q 20266-K 17 Aug 2026; Zacks SCR
RAD204Cohort 3 enrollment by 3Q 2026; escalation complete 1H 2027; Phase 2 in 2027Zacks SCR (Aug 2026)
RAD202Cohort 4 dosing (DSMC Aug 2026)Press release 20 Aug 2026
RV-01Cohort 2 at 70 mCi underwayPress release 26 Aug 2026
Radiopharm VenturesFinal selection of two further candidates in 2026Half-year release Jan 2026
Cash runwayForecast to fund operations through fiscal 2027, dependent on access to additional fundingFY2026 20-F
Financial targetsNo revenue or profitability targets issued—

Products & Services

No product is approved for commercial sale anywhere. All pricing is not publicly disclosed. Programs are listed in order of maturity.

RAD101 — ¹⁸F-pivalate (imaging, brain metastases)

Description: Small-molecule PET tracer targeting fatty acid synthase (FASN), an enzyme over-expressed in many solid tumours including brain metastases; labelled with fluorine-18. Licensed from Imperial College London (via Cancer Research Technology per 20-F XBRL references).

Indication: Patients with suspected recurrence of brain metastases after radiotherapy, where MRI cannot reliably distinguish viable tumour from radiation-induced treatment effects (radionecrosis).

Status: Company-sponsored US Phase 2b (N=30) completed; topline (22 Jul 2026) showed 93% (28/30) concordance between PET and MRI across evaluable lesions, meeting the primary endpoint; earlier interim reads were 92% (first 12 patients, Dec 2025) and 90% (18/20, Mar 2026). FDA Fast Track (June 2025). End-of-Phase 2 meeting held 1 Oct 2026; minutes expected around early November 2026. Late-breaking oral presentation selected for the 2026 Society for Neuro-Oncology meeting.

Key capabilities: F-18's half-life permits regional distribution from cyclotron radiopharmacies and fits existing PET infrastructure (company investor materials, July 2026).

Manufacturing/distribution: Siemens Healthineers (supply agreement, 7 Apr 2026) to manufacture and distribute F-18 RAD101 doses for the US Phase 3.

Target customer: Neuro-oncology, radiation oncology and nuclear medicine centres; company cites roughly 300,000 US patients as the addressable population (Kalkine summary of July 2026 investor deck).

Next milestone: Phase 3-readiness by year-end 2026; Phase 3 start targeted 4Q 2026 (Zacks SCR; RTTNews).

Pricing model: Not publicly disclosed.

177Lu-RAD202 — HER2-targeted nanobody (therapy)

Description: Single-domain antibody (nanobody) against HER2 conjugated to lutetium-177; licensed from NanoMab Technology.

Indication: Advanced HER2-positive solid tumours (breast, gastric and others).

Status: Phase 0/1 "HEAT" first-in-human dose-escalation trial. Dosing progressed from 30 mCi to 75 mCi (by Dec 2025), DSMC endorsed 130 mCi (Apr 2026), and a further DSMC recommendation to advance to Cohort 4 (20 Aug 2026). Initial data presented at AACR 2026 showing tumour uptake in HER2-positive lesions.

Target customer: Oncology centres treating HER2-positive metastatic disease, including post-ADC settings.

177Lu-RAD204 — PD-L1-targeted nanobody (therapy)

Description: Nanobody against PD-L1 radiolabelled with Lu-177; licensed from NanoMab.

Indication: Metastatic non-small cell lung cancer (NSCLC) and other PD-L1-positive tumours.

Status: Phase 1 dose escalation: Cohort 1 at 30 mCi, Cohort 2 at 60 mCi (DSMC May 2025), Cohort 3 at 90 mCi approved. Early signal: two of three patients in the 30 mCi cohort had stable disease for 5.5 months versus a cited historical PFS of 3.5 months on standard of care (Jan 2026 4C). Zacks SCR expects Cohort 3 enrollment completion in 3Q 2026, escalation completion in 1H 2027 and a Phase 2 start in 2027.

177Lu-RV-01 (Betabart) — 4Ig-B7-H3 monoclonal antibody (therapy)

Description: Lu-177-labelled monoclonal antibody selective for the 4Ig isoform of B7-H3, an immune-checkpoint protein highly expressed in tumours with limited expression in healthy tissue. First therapeutic from Radiopharm Ventures (MD Anderson JV).

Status: FDA IND cleared July 2025; first-in-human Phase 1/2a initiated (by April 2026); first patient of Cohort 2 dosed at 70 mCi (26 Aug 2026). Preclinical data showed tumour shrinkage and prolonged survival.

Indication: B7-H3-expressing solid tumours (multiple types).

RAD402 — ¹⁶¹Tb-anti-KLK3 monoclonal antibody (therapy)

Description: Humanised antibody against kallikrein-3 (KLK3/PSA), labelled with terbium-161 (beta plus Auger/conversion electrons); licensed from Diaprost (with Fredax).

Indication: Metastatic or locally advanced prostate cancer.

Status: Bellberry HREC approval (Nov 2025) for first-in-human Phase 1 in Australia; trial initiated by April 2026. Tb-161 supplied by TerThera (Netherlands); radiolabelling by Cyclotek (Australia).

Differentiation: Non-PSMA target and early use of Tb-161 in a company-sponsored therapeutic trial.

RAD301 — ⁶⁸Ga-Trivehexin (imaging, pancreatic cancer)

Description: Gallium-68 labelled peptide targeting αvβ6-integrin, a marker of invasion and metastatic growth associated with poor survival in several carcinomas, notably pancreatic; licensed from TRIMT (Technical University of Munich spin-out).

Status: Phase 1 imaging trial in pancreatic ductal adenocarcinoma (PDAC); positive data announced 9 Sep 2026 showing favourable safety and biodistribution and significant tumour uptake in evaluable PDAC patients. Prior to Radiopharm's program, 99 patients had been imaged under compassionate use or investigator-initiated studies without reported safety issues (BusinessNews WA, June 2024).

RAD302 — ¹⁷⁷Lu-αvβ6-integrin (therapy)

Description: Therapeutic pair to RAD301; potential in pancreatic, head-and-neck, lung and colorectal cancers.

Status: Preclinical; spending on the TRIMT family fell from A$1.88M (FY2025) to A$0.92M (FY2026).

Radiopharm Ventures follow-on candidates

  • Two additional preclinical candidates showed early positive results, with final candidate selection targeted in 2026 (Jan 2026 half-year release). Zacks SCR references a candidate designated AKY-2519 in IND-enabling studies; its origin and target are not detailed in primary sources reviewed.

Other licensed / historical assets

AssetStatusSource
NeoIndicate sublicenceMinimal spend (A$0.35M FY2026); contingent consideration written to nil in FY2026FY2026 Appendix 4E
UCLA licenceNo FY2026 spendFY2026 Appendix 4E
Pharma15 assetFully impaired at 30 Jun 2026; milestones considered extremely unlikelyFY2026 20-F
LRRC15 mAb (now Lantheus LNTH-2403)Divested to Lantheus (2024)Lantheus Q2-2024 8-K
TROP2 nanobody (now Lantheus LNTH-2404)Divested to Lantheus (2024)Lantheus Q2-2024 8-K

Services

  • Development services to Lantheus (Australia), generating A$2.77M revenue in FY2026 — the company's only revenue line.

Financial Narrative

All figures A$ millions unless stated; fiscal years ending 30 June. FY2021 was a ~5-month stub from incorporation (pre-tax loss A$1.16M per StockAnalysis) and is excluded from the five-year window.

Income statement

Sources: FY2026 Appendix 4E (FY2025–FY2026 detail); FY2025, FY2024, FY2023 Appendix 4E and FY2022 Annual Report (net loss lines); FY2022–FY2024 pre-tax per StockAnalysis aggregator; FY2024 attributable loss derived from the FY2025 Appendix 4E disclosure that attributable loss fell 20.2% to A$36.70M; FY2022 revenue derived from FY2023 Appendix 4E statement that revenue rose 100% from nil.

Margins (FY2025–FY2026; revenue base too small for meaningful ratios).

Revenue CAGR FY2023–FY2026 (derived): ~112% per year — arithmetically correct but analytically meaningless given a sub-A$4M contract-services base.

Commentary. The FY2026 loss widened 48.5% (attributable +50.3%) almost entirely because R&D expense rose 81.6% to A$49.96M, reflecting simultaneous execution of one Phase 2b and five Phase 1 programs. Within R&D, A$5.27M was non-cash impairment (Pharma15 and related). Partially offsetting were a A$1.67M gain on remeasurement of contingent consideration (versus a A$4.07M charge in FY2025) and a modest gross profit on Lantheus services. G&A rose 10.8% to A$16.22M, driven by employee benefits (A$11.19M), higher insurance (A$0.34M vs A$0.11M — consistent with a US listing) and investor relations. FY2025 was the inflection where the US listing, Lantheus revenue and the capital raise of mid-2024 reshaped the P&L; FY2026 is the inflection where clinical execution outran funding.

Balance sheet

Sources: FY2026 Appendix 4E (FY2025–26 balance sheet; equity rollforwards from 1 July 2024); FY2024 Appendix 4E (FY2022–FY2024 equity rollforward and cash); FY2023 Appendix 4E (FY2022–23 cash and NTA). Accumulated losses at FY2022 are the opening FY2023 balance. Goodwill: none recognised.

Commentary. The balance sheet is debt-free but not unencumbered: A$25.8M of contingent consideration (Diaprost A$8.90M, TRIMT A$7.76M, NanoMab A$5.55M — payable in shares — Pivalate A$2.03M, MD Anderson A$1.54M) sits against A$38.2M of capitalised licences. The most important asset after cash is the A$15.88M accrued R&D Tax Incentive receivable from the Australian Taxation Office; post year-end, A$5.78M relating to the FY2025 claim was received. Working capital collapsed from A$24.9M to A$3.0M, and net tangible assets per share turned more negative, which is the arithmetic behind the going-concern material uncertainty.

Cash flow

Source: FY2026 Appendix 4E statement of cash flows. FY2022–FY2024 cash-flow detail not reproduced in the sources reviewed. FY2025 financing also included A$1.90M borrowing repayment and a A$1.69M settlement with Lind.

Commentary. Operating cash burn rose 44% to A$52.8M. Zacks SCR's analysis of the June-quarter 4C itemises FY2026 cash uses as R&D A$43.4M, staff A$11.0M, administration and corporate A$4.2M and marketing A$0.39M. Customer receipts collapsed to A$0.54M as Lantheus services were billed but not yet collected (trade receivables A$1.23M at year end) and as deferred revenue unwound.

Ratios

ROIC, net debt/EBITDA, interest coverage and the cash conversion cycle are not meaningful for a pre-revenue, debt-free developer with negative EBITDA. FY2025 ROE of -109.2% matches the figure displayed by iTiger, corroborating the derivation.

Half-year and quarterly datapoints (FY2026)

Sources: Q1 FY26 4C (via Zacks/Kalkine); Half-Year Report 31 Dec 2025 (6-K); FY2026 Appendix 4E. The half-year interim review opinion was unmodified.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionOwnershipRoleSource

Radiopharm Theranostics Limited

Australia

Parent

Listed holding/operating company; IP licensee; R&D tax-incentive claimant

FY2026 20-F

Radiopharm Theranostics (USA), Inc.

Nevada, USA

100%

US operations; JV partner

1stOncology (Lantheus agreement terms); FY2026 Appendix 4E

Radiopharm Ventures, LLC

United States

87.5% (FY2026); 75% (FY2025); 51% at formation

JV with MD Anderson developing therapeutics on MD Anderson IP (RV-01 / Betabart and follow-on candidates)

FY2026 Appendix 4E

Pharma15 Corporation

Not stated

Acquired Mar 2023; asset fully impaired and "other equity" derecognised in FY2026

Former acquired IP

FY2026 20-F; FY2026 Appendix 4E

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment revenue (AUD Mn)

0.2993.6332.768

Segment revenue YoY growth (%)

2.41,114.3-23.8

Segment pre-tax loss (AUD Mn)

-47.85-38.24-56.90

Segment operating loss (AUD Mn)

—-38.17-56.78

Segment gross margin (%)

—1.19.5

Contribution to group revenue (%)

100100100

Revenue by Segment and Segment Assets & Liabilities

R&D by program (AUD Mn)FY2025FY2026

NanoMab (RAD202 HER2 and RAD204 PD-L1 nanobodies)

7.18515.070

R&D Ventures (MD Anderson JV incl. RV-01)

5.99011.041

hu-PSA antibody Diaprost (RAD402)

2.9257.011

Pivalate Imperial (RAD101)

5.1846.153

αvβ6 Integrin TRIMT (RAD301/302)

1.8770.918

Neoindicate

0.4370.352

UCLA

0.2260

Consulting fees R&D

0.9301.324

Amortisation of licensed IP

2.5882.699

Impairment losses

05.267

Other

0.1720.128

Total R&D expense

27.51549.963

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from contracts with customers (AUD Mn)

00.2920.2993.6332.768

Cost of sales (AUD Mn)

———3.5942.504

Gross profit (AUD Mn)

———0.0390.263

Other income incl. R&D tax incentive (AUD Mn)

———10.25710.734

General and administrative expense (AUD Mn)

———14.63816.216

R&D expense (AUD Mn)

———27.51549.963

Share-based payments expense (AUD Mn)

———1.8952.406

Movement in contingent consideration, gain positive (AUD Mn)

———-4.0701.671

Operating loss (AUD Mn)

———-38.174-56.784

EBITDA, derived = operating loss plus amortisation and depreciation (AUD Mn)

———-35.579-54.078

Pre-tax loss (AUD Mn)

-30.38-34.57-47.85-38.239-56.896

Net loss after tax, total group (AUD Mn)

-30.420-34.611-47.949-38.342-56.950

Net loss attributable to owners (AUD Mn)

-30.420-34.611-45.99-36.703-55.149

Basic and diluted EPS (A$ cents)

———-1.76-1.79

Dividends per share (A$ cents)

00000

Margin Analysis (%)

MetricFY2025FY2026

Gross margin (%)

1.19.5

Operating margin (%)

-1,050.6-2,051.5

EBITDA margin, derived (%)

-979.2-1,953.8

Net margin (%)

-1,055.3-2,057.5

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Cash and cash equivalents (AUD Mn)

26.97911.69918.57529.1174.138

Trade and other receivables incl. accrued R&D tax incentive (AUD Mn)

———10.40017.447

Total current assets (AUD Mn)

———39.85421.926

Intangible assets — licensed IP (AUD Mn)

———46.57438.162

Total assets (AUD Mn)

———86.48260.134

Total current liabilities (AUD Mn)

———14.93318.897

Contingent consideration liabilities, total (AUD Mn)

———32.09825.774

Total liabilities (AUD Mn)

———43.61037.810

Borrowings, short-term (AUD Mn)

———00

Borrowings, long-term (AUD Mn)

———00

Net debt, negative = net cash (AUD Mn)

———-29.117-4.138

Total equity (AUD Mn)

62.96345.57927.35342.87222.324

Share capital (AUD Mn)

86.75997.230100.682176.558209.933

Accumulated losses (AUD Mn)

30.90565.354111.339145.733199.660

Working capital, derived (AUD Mn)

———24.9213.029

Net tangible assets per share (A$ cents)

2.70-3.82—-0.16-0.45

Ordinary shares outstanding at year end (millions)

——460.3672,364.9503,544.216

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD Mn)

———5.3540.536

Payments to suppliers and employees (AUD Mn)

———-42.800-58.354

R&D tax incentive received in cash (AUD Mn)

———04.485

Net operating cash flow (AUD Mn)

———-36.645-52.783

Capex on PP&E (AUD Mn)

———00

Licence-fee liability payments (AUD Mn)

———-1.227-5.421

Proceeds from IP sale (AUD Mn)

———2.9980

Net investing cash flow (AUD Mn)

———1.771-5.421

Free cash flow, OCF less capex (AUD Mn)

———-36.645-52.783

Free cash flow incl. licence payments, derived (AUD Mn)

———-37.872-58.204

Gross equity proceeds (AUD Mn)

———53.97835.378

Net financing cash flow (AUD Mn)

———45.43233.375

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

ROE on average total equity, derived (%)

-63.8-131.5-109.2-174.7

ROA on average total assets, derived (%)

———-77.7

Current ratio (x)

——2.671.16

Debt to equity (x)

——00

Asset turnover on average assets, derived (x)

———0.038

R&D as % of revenue (%)

——757.31,805.1

Key Financials

Metric30 Sep 202531 Dec 202530 Jun 2026

Cash (AUD Mn)

19.0434.524.14

Net operating cash outflow year-to-date (AUD Mn)

—22.6752.78

Half-year loss after tax (AUD Mn)

—28.24—

Net assets (AUD Mn)

—49.9422.32

Revenue Lines

Revenue lineFY2023FY2024FY2025FY2026

Lantheus development services, Australia (AUD Mn)

——3.6332.768

Other / unspecified contract revenue (AUD Mn)

0.2920.29900

Total revenue (AUD Mn)

0.2920.2993.6332.768

Geographic Revenue

RegionFY2024FY2025FY2026

EMEA revenue (AUD Mn)

000

Capital Markets Data (USD)

Metric31 Oct 202530 Jan 202611 May 202631 Jul 202615 Sep 20268 Oct 2026

RADX ADS close (USD)

5.265.054.003.151.521.11

Firm Details

FirmRating / targetDateNoteSource

Zacks Small-Cap Research

Valuation US$12.50/ADS

3 Aug 2026 (prior US$13.50)

Company-sponsored research

Zacks SCR

H.C. Wainwright

Buy, US$6 target

Initiation date not confirmed

Also placement agent for the July 2026 RDO

StockAnalysis news feed

TipRanks consensus

Average target US$18.75

Stale; date unclear

Aggregator

TipRanks

Share Price & Returns

DateInstrumentPriceGross proceeds (AUD Mn)Source

Jul–Sep 2024

Institutional placement (multiple tranches)

A$0.04

62.5

FY2026 Appendix 4E share table

Aug 2024

Lantheus strategic placement

A$0.05

7.48

Same

Jan 2025

Lantheus strategic placement

A$0.06

8.0

Same

Oct–Dec 2025

Institutional placement and SPP

A$0.03

35.38

Same

Jul–Sep 2026

Australian placement plus US RDO

A$0.015 / US$3.16 per ADS

~12.5

ASX 24 Jul 2026

Sep 2026

SPP (up to A$6M; A$3M shortfall commitments)

lower of A$0.015 or 2.5% discount to 5-day VWAP

Not confirmed

ASX 24 Jul 2026

Ongoing

Leerink ATM (ADSs)

Market

Capacity up to US$9.3M (20-F)

FY2026 20-F

Analyst Conclusions

Management guidance. No financial guidance is provided. Operational guidance: receive FDA EOP2 minutes in roughly November 2026; be Phase 3-ready for RAD101 by year-end 2026 with a trial start targeted for 4Q 2026; continue escalation in RAD202 (Cohort 4), RAD204 (Cohort 3, 90 mCi), RV-01 (Cohort 2, 70 mCi) and RAD402; and pursue strategic partnering. The 20-F states current cash is forecast to fund operations through fiscal 2027, contingent on access to additional funding.

Consensus growth expectations. No formal revenue consensus exists. Sponsored research (Zacks) applies a 25% probability of success to RAD101 in its model (Aug 2025 report).

Bull case.

  1. De-risked diagnostic with a clear regulatory path. Three consecutive readouts at 90–93% concordance, Fast Track and a completed EOP2 meeting make RAD101 one of the more advanced novel brain-PET tracers; diagnostics typically carry lower development cost and higher probability of approval than therapeutics.

  2. Strategic-acquirer logic. Lantheus (an existing ~8–12% holder) has publicly refocused on radiodiagnostics, and Siemens Healthineers is already the Phase 3 supplier — two natural partners or acquirers for a US brain-metastasis PET franchise.

  3. Deep-value optionality. A market value near US$20M is less than book equity before the July raise and below cumulative capital invested, while five clinical programs (including a 4Ig-B7-H3 antibody owned 87.5%) provide multiple shots on goal.

Bear case.

  1. Funding precedes everything. A$4.1M of year-end cash against ~A$58M of FY2026 operating and investing outflows means a pivotal Phase 3 cannot be funded without large additional capital or a partner; the going-concern material uncertainty formalises this.

  2. Relentless dilution. Shares outstanding rose ~7.7x in two years, with options over 2.50B shares and ADR warrants outstanding; the latest raise was priced at A$0.015 and the ADS has fallen ~65% since.

  3. Listing and pipeline sprawl risk. The ADS trades near the US$1.00 Nasdaq bid threshold, and spreading A$50M of R&D across six programs leaves each therapeutic underfunded relative to big-pharma competitors.

Key catalysts and monitorables (next 12 months).

Concluding analyst verdict. Radiopharm Theranostics enters late 2026 with a sharply bifurcated profile. Scientifically and regulatorily, it has done what a small radiopharma developer is supposed to do: RAD101 has generated a consistent 90–93% concordance signal across three Phase 2b readouts, secured Fast Track status, locked in a credible Phase 3 supply chain through Siemens Healthineers, and completed its End-of-Phase 2 meeting with the FDA. Behind it sits a genuinely differentiated, if early, therapeutic portfolio — nanobody radioligands against HER2 and PD-L1, a 4Ig-B7-H3 antibody controlled through the MD Anderson joint venture, and one of the first company-sponsored terbium-161 programs. Financially, however, the company is at its weakest point since IPO. Year-end cash of A$4.1M, an operating burn above A$50M, a going-concern material uncertainty, shares outstanding that have multiplied roughly sevenfold in two years, a large option and warrant overhang, and an ADS hovering near Nasdaq's US$1 threshold mean that equity holders are funding a pivotal trial from a position of minimal leverage. The market's verdict — a valuation around US$20M despite the positive regulatory momentum — reflects the expectation of further deep-discount issuance rather than scepticism about the science alone. Our assessment is that value realisation for current holders hinges almost entirely on a non-dilutive or minimally dilutive transaction for RAD101: a regional or global licence, co-development, or acquisition by a diagnostics-focused party. Lantheus's stated pivot toward radiodiagnostics, its existing shareholding and its development-services relationship make it the most obvious counterparty, though no transaction has been announced. Absent such a deal, the base case is continued pipeline progress accompanied by heavy dilution, with per-share upside capped. We characterise the stock as a high-risk, binary special situation.


All figures sourced as cited. Derived metrics are computed from reported figures and labelled accordingly.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackground (as disclosed)Source

Paul Hopper

Executive Chairman; founder

Feb 2021

Serial biotech founder/chair; born 1956; B.A. (UNSW), FAICD

Motley Fool AU; Yahoo Finance; Stockhead

Riccardo Canevari

Managing Director and CEO

13 Sep 2021

—

FY2022 Annual Report; Simply Wall St

Phillip Hains

Executive Director, CFO; previously Company Secretary

Not confirmed

Chartered Accountant; principal of The CFO Solution (now part of Acclime Australia); specialist in listed-company finance

Pharnex; iTiger. Moomoo lists him as non-executive — discrepancy flagged

Ian Turner

Non-Executive Director

Apr 2021

Not detailed in sources reviewed; active on-market buyer (e.g., 3M shares, May 2025)

Motley Fool AU

Hester Larkin

Independent Non-Executive Director

3 Feb 2022

Managing Director of Hester Larkin Associates Consulting; prior board/trustee roles in the UK and Belgium

Motley Fool AU; FY2022 Annual Report

Noel Donnelly

Independent Non-Executive Director

By Dec 2024 (exact date not confirmed)

MBA; received 8M director options Dec 2024

Moomoo; Motley Fool AU

Dr Leila Alland

Non-Executive Director

6 Jun 2022

M.D.; continuing status not confirmed (absent from Dec 2024 director option issue)

FY2022 Annual Report; iTiger; Moomoo

Executive Leadership Team

NameTitleNotesSource

Riccardo Canevari

CEO and MD

Increased direct holding (on-market purchase of 1.5M shares at A$0.025, 2025)

Fintool

Phillip Hains

CFO

—

iTiger

Vittorio Puppo

Chief Operating Officer

~30 years in pharma and devices

FY2022 Annual Report; Yahoo Finance

Dr Dimitris Voliotis

Chief Medical Officer

Listed as CMO in current profiles

iTiger; Moomoo

Prof. David Mozley

CMO and Scientific Advisory Board Chair (per Yahoo)

—

Yahoo Finance

Dr Thomas H. Tulip

Chief Business Officer

Born 1953

Yahoo; Moomoo

Dr Scot L. Harper

SVP Clinical Operations

—

Yahoo

Bill Regan

SVP Regulatory Strategy

—

Yahoo

Dr Rama Abu Shmeis

SVP Chemistry, Manufacturing and Controls

—

Yahoo

Amritha Sushil

Company Secretary

Signed the Aug 2026 Form 6-K; earlier filings signed by Phillip Hains; Nathan Jong previously listed

6-K 28 Aug 2026; 6-K Jun 2025

Directors' Remuneration

ExecutiveTotal compensationBasis / periodSource

Riccardo Canevari

A$1.51M

Yahoo Finance "pay" field (fiscal year unspecified)

Yahoo Finance AU

Riccardo Canevari

A$2.65M (31.8% salary, 68.2% bonus/equity)

Simply Wall St (circa FY2025)

Simply Wall St

Vittorio Puppo

A$1.03M

Yahoo (FY unspecified)

Yahoo Finance AU

David Mozley

A$0.77M

Yahoo (FY unspecified)

Yahoo Finance AU

Thomas Tulip

A$0.50M

Yahoo (FY unspecified)

Yahoo Finance AU

Paul Hopper

A$0.27M

Yahoo (FY unspecified)

Yahoo Finance AU

Major Shareholders

HolderStakeBasis

Lantheus Holdings, Inc.

12.16% (Jan 2025); at least ~8.0% of 30 Jun 2026 shares on a derived floor basis (283.0M shares from the Aug 2024 and Jan 2025 placements over 3,544.2M shares), plus an undisclosed participation in the Oct 2025 placement

Market Herald; FY2026 Appendix 4E share table (derived)

Paul Hopper

Not disclosed (subscribed 82.5M shares in Sep 2024 placement; sold 1.5M Dec 2024)

Motley Fool AU

Riccardo Canevari

~0.9% (circa 2025)

Simply Wall St

Other top-10 institutional holders

Not publicly disclosed in sources reviewed (ASX top-20 list appears in the Annual Report)

—

ADS float

~5.3M ADS free float per iTiger (date unspecified)

iTiger

Competitive Landscape

Competitors by Segment

ProgramCompetitorAsset / approachPositioning vs RadiopharmSource / note

RAD101 (brain-met recurrence imaging)

Standard of care MRI (gadolinium, perfusion)

Incumbent

RAD101 is positioned as a problem-solving adjunct where MRI is equivocal

Company materials

RAD101

Blue Earth Diagnostics (Bracco)

¹⁸F-fluciclovine amino-acid PET studied for recurrent brain metastases vs radiation necrosis

——

RAD101

Telix Pharmaceuticals

Pixclara (¹⁸F-floretyrosine/FET) glioma imaging

—

Telix H1-2025 release

Platform / commercial radiopharma

Telix Pharmaceuticals

Illuccix/Gozellix PSMA imaging, therapeutics pipeline

Scale leader from Australia; FY2025 revenue US$803.8M

Telix FY2025 results

Platform / commercial radiopharma

Lantheus Holdings

Pylarify, Definity, NeuraCeq

Partner and shareholder; also potential competitor in diagnostics; FY2025 revenue US$1.54B

Lantheus FY2025 8-K

Prostate therapy (RAD402)

Novartis

Pluvicto (¹⁷⁷Lu-PSMA-617), Lutathera

Entrenched PSMA standard; RAD402 targets KLK3 instead

General market knowledge

Prostate therapy (RAD402)

Clarity Pharmaceuticals (ASX: CU6)

Copper-64/67 SAR-bisPSMA theranostics

Australian peer competing for the same investor pool

—

Multiple solid tumours

Eli Lilly (POINT Biopharma)

Radioligand pipeline

Big-pharma capital and manufacturing

General market knowledge

Multiple solid tumours

Bristol Myers Squibb (RayzeBio)

Actinium-225 radioligands

Alpha-emitter platform

General market knowledge

Multiple solid tumours

AstraZeneca (Fusion Pharmaceuticals)

Actinium-225 radioconjugates

Alpha-emitter platform

General market knowledge

Multiple solid tumours

Perspective Therapeutics

Lead-212 peptides

US small-cap peer

—

Isotope / platform

ITM Isotope Technologies Munich

Isotopes and own pipeline

Supplier and potential competitor

Zacks SCR

B7-H3 (RV-01)

B7-H3 antibody-drug conjugates in development across large pharma

ADC modality

Competing modality for the same target

General market knowledge

HER2 (RAD202)

Approved HER2 ADCs and antibodies

Non-radioactive standard of care

RAD202 must show benefit in pretreated settings

General market knowledge

Peer Comparison FY2026

MetricRadiopharm (FY2026, A$)Telix (FY2025, US$)Lantheus (FY2025, US$)

Revenue

A$2.77M

US$803.8M

US$1.54B

Revenue growth

-23.8%+56%—

Profitability

Net loss A$56.95M

Net loss US$5.3M; adjusted EBITDA US$216.4M

GAAP diluted EPS US$3.41

R&D intensity

~1805% of revenue

FY2026 R&D guidance US$200–240M

—

Cash

A$4.14M

US$141.9M

US$359.1M

Company Snapshot

14

Employees

$20.7M

Market Cap

2021

Founded

Carlton South, Australia

Headquarters

SWOT Analysis

Strengths

  • RAD101 met its Phase 2b primary endpoint with 93% (28/30) PET–MRI concordance (Jul 2026), consistent with earlier interims of 92% and 90%.
  • FDA Fast Track designation for RAD101 (Jun 2025) and a completed End-of-Phase 2 meeting (Oct 2026).
  • Siemens Healthineers committed to manufacture and distribute F-18 RAD101 for the US Phase 3 (Apr 2026).
  • Five clinical-stage assets across four isotopes and four molecular formats (Q3 FY26 4C; investor deck Jul 2026).
  • Strategic shareholder Lantheus invested at premiums of 47% (A$0.05) and 150% (A$0.06) in 2024–2025 (FY2026 Appendix 4E share table; Market Herald).
  • Debt-free balance sheet with zero borrowings at 30 Jun 2026 and a A$15.88M accrued R&D tax-incentive receivable (FY2026 Appendix 4E).

Weaknesses

  • Cash of A$4.14M at 30 Jun 2026 versus A$52.78M annual operating outflow (FY2026 Appendix 4E).
  • Going-concern material uncertainty in the FY2026 audited accounts (FY2026 Appendix 4E; 20-F).
  • Share count rose from 460M (Jul 2024) to 3,544M (Jun 2026), with ~833M more shares from the July 2026 raise plus SPP shares and options over 2.50B shares (FY2026 Appendix 4E; 20-F).
  • 100% revenue concentration in one customer (Lantheus), and revenue fell 23.8% in FY2026.
  • No manufacturing capability; reliance on contractors stated in 20-F risk factors.
  • Executive-heavy board with a founder Executive Chairman (governance profile per director register).

Opportunities

  • Registrational Phase 3 for RAD101 targeted to start 4Q 2026, potentially leading to the company's first product.
  • Partnering/licensing of RAD101 to a diagnostics-focused major — Lantheus explicitly refocused on radiodiagnostics in Feb 2026.
  • RAD204 early signal: 2 of 3 NSCLC patients with 5.5-month stable disease at the lowest dose (Jan 2026 4C).
  • RV-01 targets B7-H3, a target of intense industry interest; the company now owns 87.5% of the JV.
  • RAD301 positive Phase 1 PDAC imaging data (Sep 2026) could support a Phase 2 or out-licensing.
  • Potential receipt of the A$15.88M R&D tax-incentive receivable provides non-dilutive cash in FY2027.

Threats

  • Further deep-discount equity raises: the July 2026 placement was priced 21.1% below the last close and ADS fell from US$3.15 (31 Jul) to US$1.11 (8 Oct 2026).
  • Nasdaq minimum bid price risk: ADS at US$1.11 on 8 Oct 2026 with a pre-market quote of US$1.00 on 9 Oct (StockAnalysis).
  • FDA may require a larger or differently designed Phase 3 than anticipated (minutes pending).
  • Competitive brain-imaging tracers (amino-acid PET such as fluciclovine and FET).
  • Changes to the Australian R&D Tax Incentive would reduce a material funding source (20-F risk factor).
  • Contingent milestone obligations (A$25.77M) crystallise as programs succeed, absorbing cash or shares.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025DSMC clears RAD204 Cohort 2 at 60 mCi FY2025 results releaseDose escalation progresses
23 May 2025Director Ian Turner buys 3M shares (~A$87k) Motley Fool AUInsider buying signal
11 Jun 2025FDA Fast Track for RAD101 6-K Jun 2025Regulatory de-risking; eligibility for rolling review
12 Jun 202530.97M shares issued at A$0.025 for a milestone FY2026 Appendix 4E share tableLicence milestone settled in equity
Jun 2025RV-01 preclinical data (biodistribution, tumour uptake) FY2025 results releaseSupports IND
Jul 2025FDA clears RV-01 IND FY2025 results releaseFirst MD Anderson JV therapeutic enters clinic
29 Jul 2025FY2025 results; cash A$29.12M; runway to mid-2026 BioSpaceFunding horizon flagged
29 Aug 2025FY2025 Appendix 4E: revenue A$3.63M (+1114%), attributable loss A$36.7M (-20.2%) Appendix 4E FY2025First meaningful revenue (Lantheus)
18 Sep 2025FY2025 Form 20-F filed edgar.toolsUS reporting
7 Oct 2025FY2025 Annual Report released Company websiteGovernance disclosure
Oct 2025A$35M placement at A$0.03 plus A$5M SPP; Lantheus participates Kalkine; FintoolRunway extended into 2027 (management guidance at the time)
28 Oct 2025Q1 FY26 4C: cash A$19.0M; R&D refund A$4.6M Zacks SCRLiquidity update
18 Nov 2025Ethics approval for RAD402 Phase 1 (Tb-161) GlobeNewswireFifth clinical program
20 Nov 2025AGM: all resolutions carried FintoolGovernance
Dec 2025RAD101 Phase 2b interim (first 12): 92% concordance Half-year releaseEarly efficacy signal
Dec 2025ATM with Leerink Partners established Half-year 6-K; FY2026 20-FFlexible funding (capacity cited as US$18.9M in half-year report and US$9.3M in 20-F — discrepancy likely reflects baby-shelf limits)
12 Jan 2026Radiopharm Ventures stake raised to 87.5% FintoolGreater JV economics
28 Jan 2026Half-year 4C: cash A$34.5M Fintool; Zacks SCRPost-raise liquidity
Feb 2026Half-year report: loss A$28.2M; net assets A$49.9M; unmodified review StockTitanBurn acceleration evident
26 Feb 2026Lantheus announces refocus on radiodiagnostics and alternatives for therapeutic assets Lantheus 8-KPartner strategy shift (external)
Mar 2026RAD101 second interim: 90% (18/20); investor conference outlines FDA engagement MarketBeat (via LongPort); 1stOncologyConsistency of signal
7 Apr 2026Siemens Healthineers RAD101 supply agreement BioSpacePhase 3 supply readiness
Apr 2026Final patient dosed in RAD101 Phase 2b; RAD202 HEAT data at AACR; RAD202 DSMC to 130 mCi Q3 FY26 4CMultiple program advances
23 Apr 2026Q3 FY26 4C; RV-01 and RAD402 trials initiated ASXFive clinical programs active
22 Jul 2026RAD101 Phase 2b topline: 93% (28/30) Zacks SCRPrimary endpoint met
24 Jul 2026A$12.5M raise (A$6.7M at A$0.015 plus US$4.1M RDO at US$3.16/ADS) and A$6M SPP; attaching options at A$0.018 and ADR warrants at US$3.79, both expiring 31 Jul 2029 ASX 24 Jul 2026; 6-K 27 Jul 2026Deeply discounted (21.1% to last close) dilutive financing
31 Jul 2026Q4 FY26 4C: FY cash burn ~A$58M incl. investing; cash A$4.1M Press release; Zacks SCRLiquidity crunch
17 Aug 2026EOP2 meeting scheduled for 1 Oct 2026 6-K 17 Aug 2026Regulatory path
20 Aug 2026DSMC recommends RAD202 Cohort 4 Press releaseEscalation continues
26 Aug 2026RV-01 Cohort 2 first patient at 70 mCi Press releaseJV asset progresses
28 Aug 2026FY2026 Appendix 4E: loss A$56.95M; going-concern material uncertainty 6-K 28 Aug 2026Key risk crystallised in accounts
9 Sep 2026Positive RAD301 Phase 1 PDAC imaging data Press releaseOptionality in pancreatic imaging
~11 Sep 2026EGM for tranche 2, SPP, options and ADR warrants (outcome not confirmed in sources reviewed) ASX 24 Jul 2026Completes July raise
14 Sep 2026Late-breaking oral at SNO 2026 for RAD101 StockTitan news listScientific visibility
15 Sep 2026ADS falls 24.4% to US$1.52 StockAnalysisShare overhang / settlement of new securities likely
23–24 Sep 2026424B3 prospectus and registration effectiveness (resale-related) StockTitan filings listAdditional tradable supply
30 Sep 2026FY2026 Form 20-F filed SECGoing-concern language; runway through FY2027 contingent on funding
5 Oct 2026EOP2 meeting with FDA completed; Phase 3 readiness activities underway 6-K / ASX 5 Oct 2026Major de-risking pending minutes
5–8 Oct 2026ADS declines to US$1.11 StockAnalysisMarket scepticism despite regulatory progress

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue from contracts with customers rose from AUD 0 Mn in FY2022 to AUD 2.8 Mn in FY2026.
Radiopharm Theranostics Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from contracts with customers00.30.33.62.8
Cost of sales———3.62.5
Gross profit———00.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.